products as well as operations, record maintenance and housekeeping, is of a much higher order compared with Indian authorities’, it allows proper hearing to companies found violating its norms.
“Since the FDA is a representative of US consumers, it is vigilant. However, the regulator checks GMP compliance on a company to company basis and recent events are not expected to generate any negative perception of generic drugs made by Indian firms,” said Sarabjit Kour Nangra, vice-president (research) and pharma expert at Angel Broking.
Kelly added that the FDA’s inspection and compliance processes ensure that “companies understand the risks associated with their product’s processes and assure they remain compliant to regulations”.
Prior to imposing the ban on Ranbaxy’s Mohali facility, FDA in its warning documents sent to the company had stated that while an inspection initiated on July 5, 2012, revealed that a tablet was out of its specified weight limit, no investigation was made (by Ranbaxy) to find the root cause, to develop actions to prevent this type of deviation from recurring, and no documented follow-up was conducted.
According to pharma experts, the heart of good manufacturing is documentation and, hence, each step must be recorded and validated to ensure there is no deviation from procedure.
According to Kelly, the number of inspections by the FDA is also on the rise because under the new Food and Drug Administration Safety and Innovation Act the regulator has to achieve the same inspectional schedule for foreign facilities as domestic manufacturers, and to clear the backlog of applications by the end of the first five years. “Having these additional inspectors in-country will assist the agency in meeting our legislative mandates,” he added.
Jayati Ghose & Pallavi Ail